Rejected NIH Applicants Should Keep Trying

According to figures maintained by NIH for the past 18 years (see chart), the percentage of applicants funded on their first try varied quite a bit in the 1970s—from about 24% in 1973 to a high of more than 40% in 1975. So far in the 1980s, the success rate for first-time applicants has stabilized at just under 30%—a stability mirrored by the success rate for all NIH applicants during recent years. “Part of it is deliberate policy,” says Joseph Brackett, chief of NIH&


Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

According to figures maintained by NIH for the past 18 years (see chart), the percentage of applicants funded on their first try varied quite a bit in the 1970s—from about 24% in 1973 to a high of more than 40% in 1975.

So far in the 1980s, the success rate for first-time applicants has stabilized at just under 30%—a stability mirrored by the success rate for all NIH applicants during recent years. “Part of it is deliberate policy,” says Joseph Brackett, chief of NIH’s Reports, Analysis, and Presentations section. “We’re trying to even out the big fluctuations.” Brackett adds, though, that stability also depends to an extent on the level of funding authorized by Congress—and this level has risen in recent years.

However, first-time success rates tell only part of the story. Perseverance pays off very well indeed, according to NIH figures revealing that between 30% and 55% of each ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo